Interleukin-1- Receptor Kinase 4 Inhibition: Achieving Immunomodulatory Synergy to Mitigate the Impact of COVID-19

Front Immunol. 2021 Jun 23:12:693085. doi: 10.3389/fimmu.2021.693085. eCollection 2021.
No abstract available

Keywords: COVID-19; Cytokine release syndrome (CRS); cytokine; immunomodulator; irak4.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use
  • COVID-19 / metabolism*
  • COVID-19 Drug Treatment
  • Cytokine Release Syndrome / drug therapy
  • Cytokine Release Syndrome / metabolism*
  • Cytokines / metabolism
  • Drug Synergism
  • Humans
  • Immunomodulation
  • Interleukin-1 Receptor-Associated Kinases / genetics
  • Interleukin-1 Receptor-Associated Kinases / metabolism*
  • Pandemics
  • Protein Kinase Inhibitors / therapeutic use*
  • SARS-CoV-2 / physiology*

Substances

  • Antibodies, Monoclonal
  • Cytokines
  • Protein Kinase Inhibitors
  • Interleukin-1 Receptor-Associated Kinases